The Share

The Diamyd Medical share is traded on Nasdaq First North Growth Market (ticker : DMYD B). ISIN code: SE0005162880.

About Nasdaq First North Growth Market

Nasdaq First North Growth Market is an alternative marketplace operated by an exchange within the Nasdaq Group. Companies on Nasdaq First North Growth Market are not subject to the same rules as companies on the regulated main market. Instead they are subject to a less extensive set of rules and regulations adjusted to small growth companies. The risk in investing in a company on Nasdaq First North Growth Market may therefore be higher than investing in a company on the main market. All companies with shares traded on Nasdaq First North Growth Market have a Certified Adviser who monitors that the rules are followed. The Exchange approves the application for admission to trading.

Certified Adviser at Nasdaq First North Growth Market

FNCA Sweden AB, Humlegårdsgatan 5, Box 5807, SE-102 48 Stockholm. Tel: 08-528 00 399, E-mail: info@fnca.se.

Analysts

Analysts following Diamyd Medical:
Ludvig Svensson, Erik Penser Bank, Tel: +46 8 463 80 00. Erik Penser Bank equity research

  Quarterly Report 2 22/23, April 5 2023
It is with great pride and humility that we at Diamyd Medical begin a multi-year collaboration with JDRF, the leading global type 1 diabetes research and advocacy organization. Thanks to JDRF's very large network, strong brand and financial support, the collaboration significantly strengthens our preparations for market and further accelerates patient recruitment for the Phase 3 trial DIAGNODE-3. The collaboration is a clear sign of our progress in the field, and we are grateful to be part of the collective effort to advance the treatment of type 1...
Thanks to JDRF's very large network, strong brand and financial support, the collaboration significantly strengthens our preparations for market and further accelerates patient recruitment for the Phase 3 trial DIAGNODE-3.
Ulf Hannelius, President and CEO

Calendar

  
Data pager
Data pager
12
June 2 − June 8, 2023
BIO International Convention
June 13, 2023
Aktiespararnas Småbolagsdagar
June 23 − June 26, 2023
ADA 83rd Scientific Sessions
June 26, 2023
Extra General Meeting
 

We are dedicated to finding a cure for autoimmune diabetes through pharmaceutical development and investments in medical and stem cell technologies

 

Ten largest shareholders as of March 31, 2023

ShareholderA SharesB SharesCapital %Votes %
Avanza Pension 9 623 555 12.51 9.63
Lindkvist, Bertil 6 240 000 8.11 6.24
Nordnet Pension 3 404 205 4.43 3.41
Essen-Möller, Anders 556 223 2 813 040 4.38 8.38
Essen-Möller, Maria-Teresa 400 000 963 998 1.77 4.97
Essen-Möller, Jon 400 000 518 554 1.19 4.52
Hillborg, Erika 400 000 374 304 1.01 4.38
Esssen-Möller, Martin 400 000 355 120 0.98 4.36
Konstruktions o Försäljningsaktiebolag 725 000 0.94 0.73
Essenshaw, My 400 000 181 002 0.76 4.18
Remaining shareholders 49 171 938 63.92 49.20
Total 2 556 223 74 370 716 100.0 100.0

Order GAD for preclinical research

GAD PRODUCTS